Sirolimus en trasplante de órgano sólido pediátrico: Experiencia en 5 casos

Sirolimus (SRL) is an immunosuppressive drug increasingly used in children undergoing solid organ transplantation. SRL does not cause glucose intolerance, hypertension, nephrotoxicity or neurotoxicity offering significant potential advantages over calceneurin inhibitors (CM). Aim: To report five chi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Roque E,Jorge, Ríos M,Gloria, Vignolo A,Paulina, Pinochet V,Constanza, Schultz,Marcela, Humeres A,Roberto, Delucchi,Angela, Rius A,Montserrat, Hepp K,Juan
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2008
Materias:	Graft rejection Organ transplantation Sirolimus
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872008000500013
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872008000500013
record_format	dspace
spelling	oai:scielo:S0034-988720080005000132008-07-30Sirolimus en trasplante de órgano sólido pediátrico: Experiencia en 5 casosRoque E,JorgeRíos M,GloriaVignolo A,PaulinaPinochet V,ConstanzaSchultz,MarcelaHumeres A,RobertoDelucchi,AngelaRius A,MontserratHepp K,Juan Graft rejection Organ transplantation Sirolimus Sirolimus (SRL) is an immunosuppressive drug increasingly used in children undergoing solid organ transplantation. SRL does not cause glucose intolerance, hypertension, nephrotoxicity or neurotoxicity offering significant potential advantages over calceneurin inhibitors (CM). Aim: To report five children treated with SRL. Material and methods: A retrospective review of four children undergoing orthotopic liver transplantation (OLT) and one undergoing renal transplantation with recurrent acute rejection (RAR), chronic rejection (CR) or toxicity due to CM, treated with SRL between June 2001 and November 2006. Results: As primary immunosuppressive therapy, all patients received 3 drugs: CM (Tacrolimus (FK) or Cyclosporine), mycophenolate mofetil and steroids. Mean age at treatment with SRL was 98 months. Children undergoing OLT had a ¡ate introduction of SRL (mean time after OLT: 37 months), and mean follow-up was 24 months. In this group rescue indications of SRL were RAR in one, CR in one, thrombotic thrombocytopenic purpura (TTP) in one, food allergy in one and other CM toxicity in three. Only one did not experience adverse events due to SRL, but no one required discontinuation of SRL. There were remissions of RAR, CR, TTP and food allergy. The patient with RT was switched from FK to SRL at day 18th after RT, but he had severe neutropenia that led to discontinuation of SRL. Conclusions: SRL may be useful in pediatric solid organ transplant recipients suffering from RAR, CR, TTP, food allergy and CM toxicity. Careful attention should be directed to detect side effects and avoid severe complicationsinfo:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.136 n.5 20082008-05-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872008000500013es10.4067/S0034-98872008000500013
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Graft rejection Organ transplantation Sirolimus
spellingShingle	Graft rejection Organ transplantation Sirolimus Roque E,Jorge Ríos M,Gloria Vignolo A,Paulina Pinochet V,Constanza Schultz,Marcela Humeres A,Roberto Delucchi,Angela Rius A,Montserrat Hepp K,Juan Sirolimus en trasplante de órgano sólido pediátrico: Experiencia en 5 casos
description	Sirolimus (SRL) is an immunosuppressive drug increasingly used in children undergoing solid organ transplantation. SRL does not cause glucose intolerance, hypertension, nephrotoxicity or neurotoxicity offering significant potential advantages over calceneurin inhibitors (CM). Aim: To report five children treated with SRL. Material and methods: A retrospective review of four children undergoing orthotopic liver transplantation (OLT) and one undergoing renal transplantation with recurrent acute rejection (RAR), chronic rejection (CR) or toxicity due to CM, treated with SRL between June 2001 and November 2006. Results: As primary immunosuppressive therapy, all patients received 3 drugs: CM (Tacrolimus (FK) or Cyclosporine), mycophenolate mofetil and steroids. Mean age at treatment with SRL was 98 months. Children undergoing OLT had a ¡ate introduction of SRL (mean time after OLT: 37 months), and mean follow-up was 24 months. In this group rescue indications of SRL were RAR in one, CR in one, thrombotic thrombocytopenic purpura (TTP) in one, food allergy in one and other CM toxicity in three. Only one did not experience adverse events due to SRL, but no one required discontinuation of SRL. There were remissions of RAR, CR, TTP and food allergy. The patient with RT was switched from FK to SRL at day 18th after RT, but he had severe neutropenia that led to discontinuation of SRL. Conclusions: SRL may be useful in pediatric solid organ transplant recipients suffering from RAR, CR, TTP, food allergy and CM toxicity. Careful attention should be directed to detect side effects and avoid severe complications
author	Roque E,Jorge Ríos M,Gloria Vignolo A,Paulina Pinochet V,Constanza Schultz,Marcela Humeres A,Roberto Delucchi,Angela Rius A,Montserrat Hepp K,Juan
author_facet	Roque E,Jorge Ríos M,Gloria Vignolo A,Paulina Pinochet V,Constanza Schultz,Marcela Humeres A,Roberto Delucchi,Angela Rius A,Montserrat Hepp K,Juan
author_sort	Roque E,Jorge
title	Sirolimus en trasplante de órgano sólido pediátrico: Experiencia en 5 casos
title_short	Sirolimus en trasplante de órgano sólido pediátrico: Experiencia en 5 casos
title_full	Sirolimus en trasplante de órgano sólido pediátrico: Experiencia en 5 casos
title_fullStr	Sirolimus en trasplante de órgano sólido pediátrico: Experiencia en 5 casos
title_full_unstemmed	Sirolimus en trasplante de órgano sólido pediátrico: Experiencia en 5 casos
title_sort	sirolimus en trasplante de órgano sólido pediátrico: experiencia en 5 casos
publisher	Sociedad Médica de Santiago
publishDate	2008
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872008000500013
work_keys_str_mv	AT roqueejorge sirolimusentrasplantedeorganosolidopediatricoexperienciaen5casos AT riosmgloria sirolimusentrasplantedeorganosolidopediatricoexperienciaen5casos AT vignoloapaulina sirolimusentrasplantedeorganosolidopediatricoexperienciaen5casos AT pinochetvconstanza sirolimusentrasplantedeorganosolidopediatricoexperienciaen5casos AT schultzmarcela sirolimusentrasplantedeorganosolidopediatricoexperienciaen5casos AT humeresaroberto sirolimusentrasplantedeorganosolidopediatricoexperienciaen5casos AT delucchiangela sirolimusentrasplantedeorganosolidopediatricoexperienciaen5casos AT riusamontserrat sirolimusentrasplantedeorganosolidopediatricoexperienciaen5casos AT heppkjuan sirolimusentrasplantedeorganosolidopediatricoexperienciaen5casos
_version_	1718436379436777472

Sirolimus en trasplante de órgano sólido pediátrico: Experiencia en 5 casos

Ejemplares similares